Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | SCN2B | O60939 | 1/20 | 0.40 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094117 | 0.94 | SCN9A (0.53) | SCN9ACYP2C9CYP3A4SCN2BSCN1B | |
| SCHEMBL1094276 | 0.90 | SCN9A (0.52) | SCN9ACYP2C9CYP3A4SCN2BSCN1B | |
| SCHEMBL9923647 | 0.88 | SCN9A (0.51) | SCN9ACYP2C9CYP3A4SCN2BSCN1B | |
| SCHEMBL1094239 | 0.77 | SCN9A (0.52) | SCN9ACYP2C9CYP3A4SCN2BSCN1B | |
| SCHEMBL9924685 | 0.77 | SCN9A (0.44) | SCN9ACYP2C9CYP3A4SCN2BSCN1B | |
| SCHEMBL18882706 | 0.76 | SCN9A (0.33) | SCN9ASCN5A | |
| SCHEMBL3478009 | 0.75 | SCN9A (0.49) | SCN9ACYP2C9CYP3A4SCN2BSCN1B | |
| SCHEMBL1109029 | 0.74 | SCN9A (0.49) | SCN9ACYP2C9CYP3A4 | |
| SCHEMBL17048610 | 0.74 | SCN9A (0.34) | SCN9ASCN5A | |
| SCHEMBL9924609 | 0.73 | SCN9A (0.41) | SCN9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885CYP2C9 75/4885CYP3A4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.